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A B S T R A C T
Adiponectin and brain natriuretic peptide (BNP) are hormones produced by adipo-
cytes and myocardial cells respectively, and have emerged as important diagnostic and 
prognostic tools in cardiovascular disease. Levels of adiponectin are down-regulated 
in obese and diabetic individuals and this hormone exhibits favorable effects on ath-
erogenesis, endothelial function and vascular remodeling. On the other hand, BNP 
and the fragment N-terminal proBNP (NT-proBNP) are natriuretic peptides released 
from the heart in response to pressure and volume overload and have become di-
agnostic tools and predictors in several cardiac abnormalities, beyond heart failure. 
This brief review will discuss the prognostic significance of these two hormones and 
epidemiological and clinical data from studies will be presented.
I N T R O D U C T I O N
Adiponectin and brain natriuretic peptide (BNP) are hormones released from adi-
pocytes and myocardial cells respectively, in response to different stimuli. Adiponectin 
is the most abundant adipokine secreted by adipose tissue that may couple regulation 
of insulin sensitivity with energy metabolism.1 Decreased plasma concentration has 
been observed in patients with diabetes, metabolic syndrome and coronary artery 
disease, and this may play a key role in the development of insulin resistance. The 
exact mechanism underlying anti–inflammatory properties of adiponectin is not yet 
well understood but there is evidence that its properties may be related, in part, to 
its ability to stimulate production of nitric oxide (NO), which is considered to be the 
potent vasodilator substance produced from endothelial cells.2 Nowadays, adiponectin 
is increasingly recognized to be both a potential biomarker for the metabolic syndrome 
and a possible therapeutic target for the treatment of cardiovascular disease.
Brain natriuretic peptide is one of the three major natriuretic peptides, atrial 
natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and C-type natriuretic 
peptide (CNP), all of which share a common 17-amino-acid ring structure and have 
cardioprotective actions against volume overload.3 Although this peptide was called 
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brain (B-type) natriuretic peptide (BNP), the primary site of 
BNP synthesis is the ventricular myocardium.4 Its initial di-
agnostic value was attributed in its ability to distinguish heart 
failure from other causes of dyspnea. Moreover, recently BNP 
and NT–proBNP have been related to other cardiac diseases, 
such as stable and unstable angina, valvular heart disease and 
sudden death, adding a new angle in their diagnostic and prog-
nostic roles. In this review, the prognostic role of adiponectin 
and BNP in cardiovascular diseases will be briefly presented.
M O l e C U l A R  C h A R A C T e R I S T I C S  
A N D  f U N C T I O N  O f  A D I p O N e C T I N
The adipocyte is an active secretory cell producing several 
cytokines (adipokines) including tumor necrosis factor-α 
(TNF-α), interleukins, plasminogen activator inhibitor type 
1, leptin and adiponectin.1 Adiponectin, also called ARCP30, 
AdipoQ, apM1 and GBP28, is the most abundant adipokine 
and is increasingly recognized to be both a potential biomarker 
for the metabolic syndrome and a possible therapeutic target 
for the treatment of cardiovascular disease in obese patients.5 
It is a 30-kDa protein which was first described in 1995. It con-
sists of an N-terminal collagenous domain and a C-terminal 
globular domain which has structural similarities to tumor 
necrosis factor-α (TNF-α).6,7 The monomers of adiponectin 
have been shown to aggregate into several polymeric forms 
in plasma, including trimeric, hexameric and high-molecular 
weight oligomeric forms. Adiponectin exists in the circulation 
as a full length protein and a proteolytic smaller globular 
domain fragment. Plasma adiponectin levels in humans are 
quite high, normally ranging from 3 to 20 μg/mL and there 
is a strong negative correlation between plasma levels and 
body mass index, especially visceral adiposity.8 The expres-
sion of adiponectin in adipose tissue seems to be regulated 
by several mechanisms via humoral and neuronal pathways. 
Two adiponectin receptors were identified in 2003, AdipoR1 
and AdipoR2.9 The first, AdipoR1 is a high affinity recep-
tor for the globular C-terminal domain and is expressed 
mainly in skeletal muscles. On the other hand, AdipoR2 
has intermediate affinity for both forms of adiponectin and 
is most abundant in the liver.9 T-cadherin is a glycosylphos-
phatidylinositol (GPI) – anchored extracellular protein and 
has been demonstrated as a receptor for hexameric and high 
molecular weight adiponectin but not for trimeric or globular 
adiponectin.10 Tissue distribution of T-cadherin is widespread 
in cardiovascular system, nervous system and muscle but is not 
highly expressed in the hepatocyte, which is one of the major 
targets of adiponectin.11
There are several conditions and factors that regulate 
the metabolic function of adiponectin. Thus, insulin and 
insulin–like growth factor-1 both upregulate adiponectin 
expression, whereas TNF-a, PPAR-α and PPAR-γ agonists, 
as metformin and thiazolidinediones respectively, have the 
opposite effect.12,13 Angiotensin II also reduces adiponectin 
production probably via signaling through the angiotensin 
II type 1 receptor.14 In addition, sympathetic activation sup-
presses adiponectin expression via adrenergic β function. Most 
other factors with a significant impact on adiponectin regula-
tion have inhibitory effects. These include catecholamines, 
glucocorticoids, cytokines, prolactin, growth hormone and 
androgens.15 Adiponectin regulates metabolism and insulin 
sensitivity, at least in part, by promoting the phosphorylation 
and activation of AMP-activated protein kinase (AMPK), 
which is a stress – responsive kinase, in skeletal muscle, liver 
and adipocytes and affects many aspects of cellular metabo-
lism including glucose uptake, glucose utilization and fatty 
acid oxidation. AMPK activation is believed to be mediated 
by adiponectin binding to the cell surface receptors AdipoR1 
and AdipoR2.16
A D I p O N e C T I N  A N D  C A R D I O v A S C U l A R 
D I S e A S e
Adiponectin may be the most relevant and promising 
adipokine with respect to a better understanding of the link 
between obesity and coronary heart disease. Importantly, 
low levels have been demonstrated in patients with ischemic 
heart disease (Fig. 1). In a prospective study, men with high 
adiponectin levels were at lower risk of myocardial infarction 
than those with lower levels. This association was independent 
of common risk factors, such as diabetes or hypertension.17 Ad-
ditionally, low adiponectin levels were associated with both ca-
rotid atherosclerosis and cardiovascular disease.18 Adiponectin 
levels have also been reported to rapidly decline after acute 
myocardial infarction. The protective action of adiponectin 
against myocardial ischemia appears to be mediated by its 
fIgURe 1. Conditions associated with hypoadiponectinemia.
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ability to activate cyclooxygenase-2 (COX-2) in cardiac cells 
which has been shown to play an important cardioprotective 
role.19 These studies have additionally demonstrated that hy-
poadiponectinemia seems to be a negative prognostic indicator 
for the development of cardiovascular disease especially in 
obese patients. In patients with acute coronary syndromes, 
where a vulnerable coronary plaque is known to be the key 
feature of the pathophysiologic process, plasma concentra-
tions of adiponectin have been found significantly lower than 
those in patients with stable angina pectoris indicating thus a 
possible role of adiponectin in maintaining coronary plaque 
stability.20 Consistent with this observation, adiponectin 
levels have been significantly associated with coronary lesion 
complexity especially in men while they have not proven to be 
such a good predictor of coronary heart disease in women.21
Clinical studies have shown that patients with essential 
hypertension appear to have significantly lower plasma adi-
ponectin levels than normotensive patients. The underlying 
mechanism may be involving the effects of angiotensin II. In-
fusion of angiotensin II in rats decreased plasma adiponectin 
levels via signaling through the angiotensin II type 1 receptor.22 
Additionally, patients with essential hypertension treated with 
angiotensin II receptor antagonists or angiotensin – converting 
enzyme inhibitors, had increased adiponectin concentrations 
without affecting body mass indices. The positive correlation 
between adiponectin levels and hypertension has been found 
more significant in men compared to women.23 Moreover, hy-
peradiponectinemia is positively correlated with high-density 
lipoprotein levels and negatively with triglycerides and apoli-
poprotein (Apo) B-100. These correlations remain significant 
even after adjusting for obesity – associated variables.24 In con-
trast, low-density lipoprotein and total cholesterol do not have 
significant independent relationship to adiponectin levels.25
Although it is not clear how or whether adiponectin itself 
has anti–inflammatory properties, it is clear that adiponectin 
production by adipose tissue can be inhibited by systemic 
inflammation. Adiponectin production by adipocytes is 
inhibited by inflammatory cytokines such as TNF-α in vitro 
and this process may be mediated in part by NF-kB signaling. 
Thus, adiponectin reduces the TNF-α stimulated expression 
of adhesion molecules, the expression of the pro-inflammatory 
cytokine IL-8 in endothelial cells and inhibits the transfor-
mation of macrophages to foam cells.26 On the other hand, 
adiponectin increases the expression of the anti-inflammatory 
cytokine IL-10 and the tissue inhibitor of metalloproteinase-1 
in macrophages.27 Moreover, it has been found that expression 
of adiponectin is inversely associated with that of CRP in men 
with coronary artery disease.
Adiponectin seems to have beneficial effects in angiogen-
esis and endothelial function through the AMPK pathway 
in the vasculature, which has been identified as a regulator 
of endothelial cell nitric oxide synthase (eNOS) activation 
as well as a number of cellular responses important for the 
angiogenesis process.28 Globular adiponectin increases eNOS 
both expression and activity in endothelial cells and improves 
ox-LDL induced suppression of eNOS activity.29 Further stud-
ies have demonstrated the anti-apoptotic action of adiponectin 
in endothelial cells especially by inhibiting angiotensin II 
apoptosis in endothelial cells.30 Moreover, there is evidence 
that adiponectin promotes directly the formation and growth 
of new blood vessels stimulating endothelial cell migration and 
differentiation into capillary – like structures in vitro through 
activation of AMPK signaling pathway.28 In vascular lesions, 
adiponectin seems to suppress the proliferation of smooth 
muscle cells promoting vascular remodeling. In vitro studies 
have shown that adiponectin can inhibit the proliferation and 
direct migration of smooth muscle cells to platelet – derived 
growth factor – BB ameliorating this way the neointimal hy-
perplasia and proliferation following acute vascular injury.31 
These results are consistent with in vivo animal studies where 
adiponectin knockout mice showed an accelerated thrombus 
formation on carotid arterial injury with a He-Ne laser.
S y N T h e S I S  A N D  f U N C T I O N  O f  B R A I N 
N A T R I U R e T I C  p e p T I D e  ( B N p )
The brain natriuretic peptide (BNP) is synthesized in 
bursts as a preprohormone of 134 residues and constitutively 
released from ventricular myocytes when left ventricular wall 
stress increase. Then it is cleaved to yield a 108-amino-acid 
prohormone, which is further cleaved by an unknown pro-
tease into an inactive 76 aminoacid N-terminal fragment 
(NT-proBNP) and a 32 aminoacid active hormone (BNP). It 
must be noticed that BNP gene expression can be increased 
very rapidly in response to an appropriate stimulus such as 
tachycardia, glucocorticoids, thyroid hormones and vasoac-
tive peptides angiotensisn II and endothelin-1, independent 
of their hemodynamic effects (Fig. 2). BNP has a half-life of 
approximately 20 min, while the half-life of the more stable 
NT-proBNP is about 120 min.3,4 Normal plasma levels of 
BNP and NT-proBNP vary widely and depend on both age 
and gender. For BNP, they range from a few picograms per 
milliliter in young males to higher than 100 pg/ml in appar-
ently healthy females over 70 years old. For acutely dyspneic 
patients, some have suggested cutoffs of BNP <100 pg/ml 
and NT-proBNP <300 pg/ml to rule out heart failure. The 
biological actions of BNP are mediated through membrane 
– bound natriuretic peptide receptors A (NPRs-A) that are 
linked to a cyclic guanosine monophosphate – dependent 
signaling cascade. NT-proBNP is eliminated mainly through 
kidney clearance, while BNP is mostly eliminated either 
through binding to its receptors NPRs-A or via degradation 
by neutral endopeptidase that is present on the surface of 
endothelial cells. However, renal failure is associated with 
elevations in both BNP and NT-proBNP levels. In general, 
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BNP and NT-proBNP are reasonably correlated and both of 
them can be used in the routine clinical practice accordingly 
to each clinician’s decision.
B N p  A S  p R O g N O S T I C  B I O M A R K e R  
f O R  C A R D I O v A S C U l A R  D I S e A S e
Both BNP and NT-proBNP can predict death and cardio-
vascular events in patients presenting with acute or chronic 
heart failure (HF) and they are being studied as a possible 
screening tool.3 It must be noted that pooled results from five 
studies showed that a BNP increase of 100 pg per mL was as-
sociated with a 35% increase in risk of death.32 BNP was the 
only statistically significant independent predictor of mortal-
ity in nine studies, indicating that BNP tests potentially are 
more useful than traditional predictors of mortality (e.g., age, 
ischemic etiology, left ventricular ejection fraction, NYHA 
classification, serum creatinine levels).32 Data from the multi-
center prospective study REDHOT (Rapid ED Heart Failure 
Outpatient Trial) showed that in patients with HF admitted 
to emergency department, BNP was predictive of future HF 
events and mortality and outperformed physician assessment, 
which had a poor predictive value.33 Moreover, the response of 
plasma BNP to therapy was illustrated in a study enrolling 102 
patients with severe HF who were studied at baseline and three 
months after optimized treatment including ACE inhibitors, 
beta blockers and digoxin. Optimized therapy was associated 
with significant reductions in plasma BNP (917 at baseline to 
285 pg/mL) as well as in other neurohumoral factors such as 
norepinephrine.34 Additionally, data from Val–HeFT (Vals-
artan Heart Failure Trial) indicate that in 4300 patients with 
congestive HF, those with the greatest increase in BNP despite 
medical therapy had the highest morbidity and mortality.35 
Moreover, several studies have indicated the usefulness of 
BNP in predicting the risk of sudden death. Particularly, in 
452 patients with severe left ventricular dysfunction (ejection 
fraction <35%) only 1% of patients with BNP <130 pg/mL 
died suddenly compared with 19% of patients with BNP ≥130 
pg/mL.36 In addition, in multivariate analyses BNP was more 
closely associated with mortality than was NYHA class or 
left ventricular ejection fraction. It must be noted that BNP, 
beyond its relationship to sudden cardiac death, may be also as-
sociated with re-hospitalizations, a setting in which traditional 
risk factors do not have any prognostic value. Furthermore, it 
is known that plasma BNP and NT-proBNP levels are lower 
in obese patients but despite this phenomenon, plasma BNP 
retains its prognostic value in this group of patients.37
Although natriuretic peptides BNP and NT-proBNP most 
often are used in patients with dyspnea and those with estab-
lished HF, their plasma concentrations have been implicated 
as predicting markers in a variety of other cardiac diseases. 
Thereby, acute coronary syndromes have been associated 
with a rise in BNP and NT-proBNP levels even in the absence 
of concomitant heart failure. The degree of elevation might 
reflect the severity of left ventricular dysfunction.38 In a study 
that enrolled 1085 patients with stable coronary artery dis-
ease for a mean follow up about 2.5 years, BNP and ejection 
fraction were the strongest predictors of future events, inde-
pendent of known risk factors. Plasma NT-proBNP appears 
to have equivalent predictive value in these patients.39 In the 
AtheroGene study data provided independent evidence that 
BNP was a strong predictor of cardiovascular risk in patients 
with stable angina independent of left ventricular systolic 
performance and known risk factors.40
The prognosting importance of plasma BNP in patients 
presenting with acute coronary syndromes was best illustrated 
in a study of 2525 patients with unstable angina and non-ST 
elevation myocardial infarction in whom plasma BNP was 
measured about 40 hours after the onset of symptoms. After 
adjusting for other predictors of risk, such as renal function, 
electrocardiographic changes, and troponin I levels, BNP 
was reputedly capable to assess the long-term risk of death 
and nonfatal cardiac events across the spectrum of acute 
coronary syndromes.41 Furthermore, persistent elevation of 
NT-proBNP 3 to 6 months after an acute coronary syndrome 
has been associated with impaired left ventricular function. 
Moreover, in a study that enrolled 4266 patients with acute 
coronary syndrome, those with elevated levels of BNP at study 
entry and with BNP levels lower than 80 pg/mL at 4 months 
tended to have only modestly increased risk (HR 1.7; 95% CI, 
1.0-2.9) compared with patients with BNP levels lower than 
80 pg/mL at both visits.42 The largest study of NT-proBNP in 
acute coronary syndromes comes from the analysis of data 
on 6809 patients presented with non-ST elevation myocardial 
infarction, in the GUSTO IV ACS trial. According to this 
analysis, NT-proBNP illustrated a stronger correlation with 
mortality than any other marker studied, including cTnT and 
CRP. In this study, patients within 24 hours of symptom onset 
fIgURe 2. Effects of Brain Natriuretic Peptide (BNP).
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with NT-proBNP values ≤98 ng/L had a significantly lower 
mortality rate at one year than those with values ≥4634 ng/L.43
Natriuretic peptides have been considered a useful clinical 
tool for monitoring patients suffering from valvular disease be-
fore and after surgery. Raised levels of BNP and NT-proBNP 
have been positively correlated with the severity of valvular 
disease. In particular, among patients with aortic stenosis 
these peptides may be a useful adjunct to classify patients 
with equivocal symptoms who are at risk for rapid progres-
sion.44 In patients who undergo surgical valve replacement or 
conservative management, natriuretic peptides levels might 
predict survival and postoperative left ventricular function. 
Also, there has been shown a significantly positive correlation 
between low levels of BNP and the risk of postoperative atrial 
fibrillation.46 In chronic aortic regurgitation, BNP levels tend 
to rise less than in aortic stenosis even when left ventricular 
dilatation has occurred.47 With respect to mitral valve disor-
ders, BNP was shown to be a marker of poor outcome in a 
study of 124 patients with mitral regurgitation, where levels 
were independently predictive of death.48
C O N C l U S I O N S
Adiponectin and BNP are targets for future research 
as prognostic markers of morbidity and mortality in several 
cardiovascular diseases. Interventions increasing adiponectin 
levels are weight loss and the administration of insulin sen-
sitizers, such as thiazolidinediones. More research is needed 
in this field as well. As we mentioned above, the beneficial 
effects of adiponectin in the atherosclerosis cascade and the 
development of cardiovascular disease are not completely 
undrerstood and future research is needed to clarify its 
pathophysiologic role.
On the other hand, BNP levels increase in several condi-
tions affecting left ventricular function, so their measurement, 
especially in asymptomatic patients, might be a useful clinical 
tool even for the primary care physician. It is expected that 
within the next few years BNP and NT-proBNP will find clini-
cal application not only in the assessment of the severity and 
the progression rate of heart failure, but also of other cardio-
vascular diseases such as unstable angina and valvular heart 
disease. The major limitation for using BNP as a prognostic 
biomarker is that specific therapeutic strategies for patients 
with raised concentrations have not yet been widely available.
R e f e R e N C e S
 1. Berg AH, Scherer PE. Adipose tissue, inflammation, and car-
diovascular disease. Circ Res 2005;96:939–949.
 2. Hattori Y, Suzuki M, Hattori S, Kasai K. Globular adiponectin 
upregulates nitric oxide production in vascular endothelial cells. 
Diabetologia 2003;46:1543–1549.
 3. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and 
biochemistry of the natriuretic peptide system. II: natriuretic 
peptide receptors. J Hypertens 1992; 10:1111–1114.
 4. Hosoda K, Nakao K, Mukoyama M, et al. Expression of brain 
natriuretic peptide gene in human heart: production in the ven-
tricle. Hypertension 1991; 17: 1152–1155.
 5. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose 
– specific gene dysregulated in obesity. J Biol Chem 1996; 
271:10697–10703.
 6. Scherer PE, Williams S, Fogliano M, et al: A novel serum pro-
tein similar to C1q, produced exclusively in adipocytes. J Biol 
Chem 1995;270:26746–26749.
 7. Shapiro L, Scherer PE: The crystal structure of a complement- 
1q family protein suggests an evolutionary link to tumor necro-
sis factor. Curr Biol 1998; 8:335–338.
 8. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an 
adipose – specific protein, adiponectin, in obesity. Biochem Bio-
phys Res Commun 1999;257:79–83.
 9. Yamauchi T, Kamon J, Ito Y, et al Cloning of adiponectin 
receptors that mediate antidiabetic metabolic effects. Nature 
2003; 423:762–769.
 10. Hug C, Wang J, Ahmad NS, et al. T-cadherin is a receptor for 
hexameric and high-molecular weight forms of Acrp30/adi-
ponectin. Proc Natl Acad Sci 2004;101:10308–10313.
 11. Huang ZY, Wu Y, Hedrick N, Gutmann DH.T – cadherin me-
diated cell growth regulation involves G2 phase arrest and re-
quires p21 (CIP1/WAF1) expression. Mol Cell Biol 2003;23:566–
578.
 12. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage prod-
uct of 30-κDa adipocyte complement-related protein increases 
fatty acid oxidation in muscle and causes weight loss in mice. 
Proc Natl Acad Sci 2001;98:2005–2010.
 13. Pajvani UB, Du X, Combs TP, et al. Structure-function studies 
of the adipocyte-secreted hormone Acrp30/adiponectin. Impli-
cations FPR metabolic regulation and bioactivity. J Biol Chem 
2003;278: 9073–9085.
 14. Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin-
angiotensin system increases adiponectin concentrations in pa-
tients with essential hypertension. Hypertension 2003;42:76–81.
 15. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin—the 
classical, resistin—the controversial, adiponectin—the promis-
ing, and more to come. Best Pract Res Clin Endocrinol Metab 
2005;19:525– 546.
 16. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimu-
lates glucose utilization and fatty-acid oxidation by activating 
AMP-activated protein kinase. Nat Med 2002; 8:1288–1295.
 17. Pischon T, Girman CJ, Hotamisligil GS, et al Plasma adiponec-
tin levels and risk of myocardial infarction in men. JAMA 2004; 
291:1730–1737.
 18. Kojima S, Funahashi T, Maruyoshi H, et al. Levels of the adipo-
cyte-derived plasma protein, adiponectin, have a close relation-
ship with atheroma. Thromb Res 2005;115:483–490.
 19. Shibata R, Sato K, Pimentel DR, et al. Adiponectin pro-
tects against myocardial ischemia–reperfusion injury through 
AMPK- and COX-2-dependent mechanisms. Nat Med 2005; 
11:1096–1103.
118
HOSPITAL CHRONICLES 4(3), 2009
treatment for heart failure are independent risk factors for mor-
bidity and mortality in patients with congestive heart failure. J 
Am Coll Cardiol 2000; 36:1587.
 35. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriu-
retic peptide and norepinephrine over time and mortality and 
morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Cir-
culation 2003;107:1278–1283.
 36. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic 
peptide predicts sudden death in patients with chronic heart 
failure. Circulation 2002;105:2392–2397.
 37. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and 
body composition on circulating levels of natriuretic peptides: 
results from the Dallas Heart Study. Circulation 2005; 112:2163.
 38. Morita E, Yasue H, Yoshimura M, et al. Increased plasma lev-
els of brain natriuretic peptide in patients with acute myocardial 
infarction. Circulation 1993;88:82–91.
 39. Richards M, Nicholls MG, Espiner EA, et al. Comparison of B-
type natriuretic peptides for assessment of cardiac function and 
prognosis in stable ischemic heart disease. J Am Coll Cardiol 
2006; 47:52.
 40. Schnabel R, Lubos E, Rupprecht HJ, et al. B-type natriuretic 
peptide and the risk of cardiovascular events and death in pa-
tients with stable angina: results from the AtheroGene study. J 
Am Coll Cardiol 2006;47:552– 558.
 41. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic 
value of B-type natriuretic peptide in patients with acute coro-
nary syndromes. N Engl J Med 2001; 345:1014.
 42. Lindahl B, Lindback J, Jernberg T, et al. Serial analyses of N-
terminal pro-B-type natriuretic peptide in patients with non-
STsegment elevation acute coronary syndromes: a Fragmin and 
fast Revascularisation during In Stability in Coronary artery dis-
ease (FRISC)-II substudy. J Am Coll Cardiol 2005;45:533– 541.
 43. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain 
natriuretic peptide and other risk markers for the separate pre-
diction of mortality and subsequent myocardial infarction in 
patients with unstable coronary artery disease: a Global Utili-
zation of Strategies To Open occluded arteries (GUSTO)-IV 
substudy. Circulation 2003;108:275
 44. Gerber IL, Stewart RA, Legget ME, et al. Increased plasma 
natriuretic peptide levels reflect symptom onset in aortic steno-
sis. Circulation 2003;107:1884 –1890.
 45. Bergler-Klein J, Klaar U, Heger M, et al. Natriuretic peptides 
predict symptom-free survival and post-operative outcome in 
severe aortic stenosis. Circulation 2004;109:2302–2308.
 46. Wazni OM, Martin DO, Marrouche NF, et al. Plasma B-type 
natriuretic peptide levels predict postoperative atrial fibrilla-
tion in patients undergoing cardiac surgery. Circulation 2004; 
110:124–127.
 47. Gerber IL, Stewart RA, French JK, et al. Associations between 
plasma natriuretic peptide levels, symptoms, and left ventricu-
lar function in patients with chronic aortic regurgitation. Am J 
Cardiol 2003;92:755–758.
 48. Detaint D, Messika-Zeitoun D, Avierinos JF, et al. B-type 
natriuretic peptide in organic mitral regurgitation: determi-
nants and impact on outcome. Circulation 2005; 111:2391.
 20. Nakamura Y, Shimada K, Fukuda D, et al. Implications of 
plasma concentrations of adiponectin in patients with coronary 
artery disease. Heart 2004;90:528–533.
 21. Lawlor DA, Davey Smith G, et al. Plasma adiponectin levels are 
associated with insulin resistance, but do not predict future risk 
of coronary heart disease in women. J Clin Endocrinol Metab 
2005;90:5677–5683.
 22. Ran J, Hirano T, Fukui T, et al. Angiotensin II infusion de-
creases plasma adiponectin level via its type 1 receptor in rats: 
an implication for hypertension-related insulin resistance. Me-
tabolism 2006;55:478–488.
 23. Mallamaci F, Zoccali C, Cuzzola F, et al. Adiponectin and es-
sential hypertension. J Nephrol 2002;15:507–511.
 24. Matsubara M, Maruoka S, Katayose S. Decreased plasma adi-
ponectin concentrations in women with dyslipidemia. J Clin En-
docrinol Metab 2002;87:2764–2769.
 25. Gavrila A, Chan JL, Yiannakouris N, et al. Serum adiponectin 
levels are inversely associated with central fat distribution and 
estrogen levels but are not directly regulated by acute fasting or 
leptin administration in humans: cross-sectional and interven-
tional studies. J Clin Endocrinol Metab 2003;88:4823–4831.
 26. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte 
derived plasma protein, inhibits endothelial NF-kappaB signal-
ling through a cAMP-dependent pathway. Circulation 2000; 
102:1296–1301.
 27. Kumada M, Kihara S, Ouchi N, et al. Adiponectin specifically 
increased tissue inhibitor of metalloproteinase-1 through in-
terleukin-10 expression in human macrophages. Circulation 
2004;109:2046 –2049.
 28. Ouchi N, Kobayashi H, Kihara S, et al. Adiponectin stimulates 
angiogenesis by promoting cross-talk between AMP-activated 
protein kinase and Akt signaling in endothelial cells. J Biol 
Chem 2004; 279:1304–1309.
 29. Hattori Y, Suzuki M, Hattori S. Globular adiponectin upregu-
lates nitric oxide production in vascular endothelial cells. Diabe-
tologia 2003;46:1543–1549.
 30. Kobayashi H, Ouchi N, Kihara S, et al. Selective suppression of 
endothelial cell apoptosis by the high molecular weight form of 
adiponectin. Circ Res 2004;94:e27–31.
 31. Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma 
protein adiponectin acts as a platelet-derived growth factor-BB-
binding protein and regulates growth factor-induced common 
post receptor signal in vascular smooth muscle cell. Circulation 
2002;105:2893–2898.
 32. Doust JA, Pietrzak E, Dobson A, et al. How well does B-type 
natriuretic peptide predict death and cardiac events in patients 
with heart failure: systematic review. BMJ 2005; 330:625.
 33. Maisel A, Hollander JE, Guss D, et al. Primary results of the 
Rapid Emergency Department Heart Failure Outpatient Trial 
(REDHOT). A multicenter study of B-type natriuretic peptide 
levels, emergency department decision making, and outcomes 
in patients presenting with shortness of breath. J Am Coll Car-
diol 2004;44:1328–1333.
 34. Maeda K, Tsutamoto T, Wadsa A, et al. High levels of plas-
ma brain natriuretic peptide and interleukin-6 after optimized 
